Navigation Links
TGen drug development teams with Oncoholdings to fight cancer
Date:1/7/2011

SCOTTSDALE, Ariz. Jan. 7, 2010 TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

Oncoholdings Inc. is a Syracuse, N.Y.-based pharmaceutical company focused on acquiring and developing the most promising preclinical and early clinical anti-cancer agents. It was founded by some of the world's leading oncology scientists and leverages the unique insights and experiences of its founders and world-class scientific advisory board.

TD2, based in Scottsdale, Ariz., provides drug development firms with expertise in moving promising laboratory discoveries through the pre-clinical, clinical and regulatory approval steps of getting new drugs to patients as quickly and safely as possible.

Under the agreement announced today, TD2 a subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen) will be the exclusive development partner for Oncoholdings' oncology portfolio. The company plans to develop as many as 15 early-stage drugs over the next three years.

"We are extremely eager to put the scientific assets of Oncoholdings on the most expeditious and precise path, moving their drug compounds safely and effectively to benefit cancer patients who so desperately need better treatments," said Dr. Stephen Gately, President of TD2 and a member of the Scientific Advisory Board of Oncoholdings.

Oncoholdings specifically targets drug candidates for development with the potential to:

  • Demonstrate superiority over standard-of-care in pre-clinical or early human trials.
  • Address significant unmet medical needs in oncology.
  • Leverage Oncoholdings' significant expertise in cancer trial design and execution.

"Through our partnership with TGen Drug Development we are confident that we have secured a team comprised of the of the world's top scientists and researchers to develop Oncoholdings' drug portfolio," said Dr. Jeffrey Evans, founder and Chief Executive Officer of Oncoholdings.

"TD2's vast knowledge and experience developing cancer therapies is important to Oncoholdings, as we are positioned to advance more than a dozen compounds with various mechanisms of action. We are very pleased to have found a partner that can meet the challenges of rapidly and effectively progressing our strategy," said Dr. Evans, who also is the former co-founder and President of Rondaxe, a leading pharmaceutical consultancy.

Oncoholdings expects to announce the acquisition of its first group of products in the first quarter of 2011. Among these first products is a novel first-in-class therapy, as well as products with clearly superior efficacy and safety profiles relative to existing therapeutics. Those interested in discussing opportunities with Oncoholdings are encouraged to contact Dr. Evans at: BusDev@oncoholdings.com


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
2. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
3. Flat Head Syndrome Linked to Developmental Delays
4. Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobiras Next-Generation CCR5 Receptor Antagonist
5. Chemical tags likely to affect metabolism, cancer development
6. The role of sleep in brain development
7. Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers
8. Antidepressants in Pregnancy May Delay Developmental Milestones
9. Secretary Clintons Approach to Development: Good Rhetoric, Little Action?
10. Sisters of Charity Health System Welcomes Mark Wiedt to its Business Development Team
11. Avoiding Dairy Due to Lactose Intolerance is Unnecessary in Most Cases and May Pose Diet and Health Risks, Concludes National Institutes of Health Consensus Development Conference Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: